Skip to main content

Table 4 225Ac (including daughters) and 227Ac (including daughters) absorbed doses for selected tissues1

From: Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

 

Absorbed dose (mGy/1 MBq 225/7Ac administered); RBE not applied

225Ac + daughters

227Ac + daughters

Alpha

Beta

Electron

Photon

Total

Alpha

Beta

Electron

Photon

Total

Red marrow

5.40E+02

1.32E+00

1.23E+00

1.28E−01

5.43E+02

6.66E−03

1.09E−04

1.05E−04

1.62E−05

6.89E−03

Spleen

3.74E+02

8.37E−01

6.64E−01

1.62E−01

3.76E+02

6.23E−03

2.06E−05

8.56E−05

2.17E−05

6.36E−03

Endosteal bone surface

2.48E+02

5.75E−01

4.19E−01

5.53E−02

2.49E+02

1.81E−02

1.26E−04

9.30E−05

4.95E−05

1.84E−02

Liver

5.59E+01

4.13E−01

1.02E−01

7.61E−02

5.65E+01

6.82E−04

4.05E−06

9.34E−06

6.98E−06

7.03E−04

Lungs

4.48E+00

7.14E−02

9.08E−03

5.22E−02

4.61E+00

1.42E−04

4.22E−06

1.16E−06

5.52E−06

1.53E−04

Kidneys

1.49E+00

2.61E−03

2.71E−03

5.42E−02

1.54E+00

5.86E−04

1.38E−06

7.21E−06

7.44E−06

6.02E−04

Pancreas

1.34E+00

1.84E−02

2.53E−03

5.12E−02

1.41E+00

4.25E−05

9.62E−07

3.31E−07

5.56E−06

4.94E−05

Adrenals

1.25E+00

2.83E−02

2.77E−03

9.02E−02

1.37E+00

3.98E−05

1.64E−06

3.59E−07

9.31E−06

5.11E−05

Heart wall

1.11E+00

1.89E−02

2.27E−03

4.90E−02

1.18E+00

3.52E−05

9.72E−07

2.86E−07

4.83E−06

4.13E−05

Thyroid

9.95E−01

1.25E−02

1.84E−03

3.60E−02

1.05E+00

3.16E−05

7.87E−07

2.46E−07

4.45E−06

3.71E−05

Ovaries

5.46E−01

7.01E−03

1.02E−03

3.75E−02

5.91E−01

2.38E−04

7.09E−07

2.95E−06

6.00E−06

2.47E−04

Thymus

3.61E−01

1.61E−02

1.29E−03

5.32E−02

4.32E−01

1.15E−05

1.87E−06

1.59E−07

5.70E−06

1.92E−05

Uterus

3.61E−01

4.94E−03

6.80E−04

3.47E−02

4.02E−01

1.15E−05

5.15E−07

1.03E−07

6.12E−06

1.82E−05

Breast

3.61E−01

4.77E−03

6.74E−04

2.02E−02

3.87E−01

1.15E−05

3.11E−07

8.85E−08

2.06E−06

1.39E−05

Brain

2.87E−01

6.25E−03

6.61E−04

1.76E−02

3.12E−01

9.12E−06

2.78E−06

1.40E−07

4.70E−06

1.67E−05

Muscle

1.89E−01

6.02E−03

5.51E−04

2.05E−02

2.16E−01

6.00E−06

1.63E−06

9.57E−08

3.26E−06

1.10E−05

Salivary glands

0.00E+00

1.03E−03

4.50E−05

2.22E−02

2.32E−02

0.00E+00

1.99E−06

5.18E−08

4.49E−06

6.54E−06

Eye lens

0.00E+00

2.49E−05

1.65E−07

1.10E−02

1.10E−02

0.00E+00

6.06E−08

5.69E−10

2.95E−06

3.01E−06

  1. 1Assuming 0.7% 227Ac in accelerator produced 225/7Ac and that 70% of the 227Th produced by beta decay of 227Ac-labeled antibody
  2. remains attached to the antibody